𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura

✍ Scribed by Nicole A. Aqui; Steven H. Stein; Barbara A. Konkle; Charles S. Abrams; Frank J. Strobl


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
67 KB
Volume
18
Category
Article
ISSN
0733-2459

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Thrombotic thrombocytopenic purpura (TTP) was once uniformly fatal. Therapeutic plasma exchange in combination with immunosuppressive and anti‐platelet agents, however, have resulted in improved survival rates of greater than 80% for patients with TTP. In spite of aggressive plasma exchange and adjuvant therapy, a number of TTP patients are refractory to treatment. In addition, up to 40% of TTP patients who initially respond to therapy eventually relapse. Alternative therapies such as splenectomy have been used with varying degrees of success in refractory and relapsing TTP patients. The usefulness of splenectomy in preventing relapse of TTP or treating those patients who are refractory to plasma exchange remains controversial. We present a single institution's experience with 14 patients who underwent splenectomy for refractory (six patients) or relapsed (eight patients) TTP since 1984. In both patient groups, splenectomy induced stable long‐term remissions. Six of six (100%) patients who were refractory to plasma exchange, survived to be discharged from the hospital, apparently free of disease. Four of eight patients (50%) who had a splenectomy for relapsing TTP went into a complete remission and had no further relapses of their disease. Moreover, in relapsing patients who failed to experience long‐term remission, the relapse rate after splenectomy was 0.3 events per patient year compared to 1.0 events per patient year prior to splenectomy. We conclude that splenectomy is a reasonable treatment option for TTP patients refractory to standard plasma exchange therapy or who have experienced multiple and/or complicated relapses. We believe this is the first series that demonstrates efficacy of splenectomy in plasma exchange‐refractory TTP. J. Clin. Apheresis 18:51–54, 2003. Β© 2003 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Cyclosporine therapy in refractory/relap
✍ Annamaria Nosari; Rosaria Redaelli; Teresa Maria Caimi; Gianni Mostarda; Enrica πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 289 KB πŸ‘ 2 views

To the editor: The interesting article by van Beers et al. states that functional studies does not offer clues as to the presence of mild pulmonary hypertension (PH) in patients with sickle cell disease (SCD) [1]. However, they did show that although not statistically significant, lung function find

Chronic relapsing thrombotic thrombocyto
✍ Pasquale, Donald; Vidhya, Rakesh; DaSilva, Karen; Tsan, Min-Fu; Lansing, Lawrenc πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 31 KB πŸ‘ 2 views

Relapsing thrombotic thrombocytopenic purpura (TTP) is a rare disorder with most individuals experiencing 1 to 5 relapses. We report a patient with 18 episodes of thrombotic thrombocytopenic purpura (TTP), the highest number of relapses thus far described. The last 11 episodes were treated with regi

Effectiveness of cryosupernatant therapy
✍ G. T. Obrador; Z. R. Zeigler; R. K. Shadduck; C. S. Rosenfeld; J. B. Hanrahan πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 332 KB πŸ‘ 2 views

## Abstract This report describes objective improvement in two patients with poorly responsive thrombotic thrombocytopenic purpura (TTP) syndromes (with cryosupernatant). The first had a partial response to plasma exchange with whole plasma (fresh frozen plasma; FFP) and responded dramatically when

Infection as a cause of early relapse in
✍ Orieji C. Illoh πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 257 KB

## Abstract Thrombotic thrombocytopenic purpura (TTP) is a rare but severe disorder characterized by hemolytic anemia, thrombocytopenia, fever, renal failure, and neurologic manifestations. Plasma exchange is the most effective treatment for this condition reducing mortality from 90% in untreated p